Iridex (IRIX) has turned around, with both its businesses (its cash cow retina business and its smaller and more recent glaucoma growth business) growing again, and there has been a great deal of cost-cutting, with more to come. Cash flow and adjusted EBITDA turned positive in Q4/25.
Pending MDR cer...
Join the Intelligence Network
Institutional Research Straight to Your Inbox
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.